New to SITC in 2019
The Society for Immunotherapy of Cancer (SITC) is pleased to announce a new corporate membership program. Designed to foster communication between industry partners and SITC leaders, organizations from all touchpoints within industry, including pharmaceutical, technology and investments firms, will be eligible for a SITC corporate membership.
A SITC corporate membership will provide organizations in the field of cancer immunotherapy and cancer research a forum in which to address common issues impacting the field with the goal of improving cancer patient outcomes.
Benefits of the SITC corporate membership program include:
- Industry Roundtable: SITC will engage industry leaders to address key issues and hurdles in the field. SITC corporate member representatives will participate in the meetings organized around key issues that affect their interests
- Private meeting with SITC leadership: SITC corporate members will receive exclusive access to SITC leadership through a private meeting each year at a location and time amenable to both parties
Dues for SITC corporate memberships will be determined by the size of the organization. The dues structure is as follows:
- Small (less than or equal to 250 employees) = $10,000 annual dues
- Medium (251-1,000 employees) = $20,000 annual dues
- Large (1,001-5,000 employees) = $35,000 annual dues
- Mega (greater than 5,000 employees) = $50,000 annual dues
SITC is proud to be a broker of new relationships among the individuals leading the next generation of cancer immunotherapy research.
To learn more about how your organization can benefit from becoming a SITC member, call (414) 271-2456 or email NNikolic@sitcancer.org.